Hydroxamic acids (therapeutics and mechanism): Chemistry, acyl nitroso, nitroxyl, reactive oxygen species, and cell signaling

Journal of Receptors and Signal Transduction

Volumn 31, Issue 1, 2011, Pages 10-19

  Kovacic, Peter ^a   Edwards, Corey L ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Anticancer; Cell signaling; Hydroxamic acid; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; HYDROXAMIC ACID DERIVATIVE; HYDROXYLAMINE; IMATINIB; NITRIC OXIDE; NITROSOBENZENE; REACTIVE OXYGEN METABOLITE; RITUXIMAB; SUBEROYL ANILIDE HYDROXAMIC ACID; UNCLASSIFIED DRUG; VORINOSTAT;

ANOREXIA; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CELL INTERACTION; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DEHYDRATION; DIARRHEA; DRUG ACTIVITY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCHEMISTRY; ELECTRON TRANSPORT; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LUNG CANCER; MEDULLOBLASTOMA; MELANOMA; NAUSEA AND VOMITING; OXIDATION; OXIDATIVE STRESS; PHYTOTOXICITY; PROSTATE CANCER; RESPIRATORY DISTRESS; RETINOBLASTOMA; REVIEW; T CELL LYMPHOMA; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME;

ANIMALS; CELLS; HUMANS; HYDROXAMIC ACIDS; NITROGEN OXIDES; NITROSO COMPOUNDS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 78649289537     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2010.497152     Document Type: Review

References (113)

1. Kovacic P, Somanathan R. Dermal toxicity and environmental contamination: electron transfer, reactive oxygen species, oxidative stress, cell signaling, and protection by antioxidants. Rev Environ Contam Toxicol 2010, 203, 119-138.
2. Howard JA, Ilyashenko G, Sparkes HA, Whiting A. Development of new transition metal catalysts for the oxidation of a hydroxamic acid with in situ Diels-Alder trapping of the acyl nitroso derivative. Dalton Trans 2007, 21, 2108-2111.
3. Cohen AD, Zeng BB, King SB, Toscano JP. Direct observation of an acyl nitroso species in solution by time-resolved IR spectrocopy. J Am Chem Soc 2003, 125, 1444-1445.
4. King SB. N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr Top Med Chem 2005, 5, 665-673.
5. Fukuto JM, Jackson MI, Kaludercic N, Paolocci N. Examining nitroxyl in biological systems. Meth Enzymol 2008, 440, 411-431.
6. Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, Hobbs AJ, Fukuto JM. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther 2007, 113, 442-458.
7. Fukuto JM, Switzer CH, Miranda KM, Wink DA. Nitroxyl (HNO): chemistry, biochemistry, and pharmacology. Annu Rev Pharmacol Toxicol 2005, 45, 335-355.
8. Fukuto JM, Dutton AS, Houk KN. The chemistry and biology of nitroxyl (HNO): a chemically unique species with novel and important biological activity. Chembiochem 2005, 6, 612-619.
9. Fukuto JM, Bartberger MD, Dutton AS, Paolocci N, Wink DA, Houk KN. The physiological chemistry and biological activity of nitroxyl (HNO): the neglected, misunderstood, and enigmatic nitrogen oxide. Chem Res Toxicol 2005, 18, 790-801.
10. Flores-Santana W, Switzer C, Ridnour LA, Basudhar D, Mancardi D, Donzelli S, Thomas DD, Miranda KM, Fukuto JM, Wink DA. Comparing the chemical biology of NO and HNO. Arch Pharm Res 2009, 32, 1139-1153.
11. Miranda KM, Ridnour L, Esprey M, Citrin D, Thomas D, Donzelli S, Wink DA, Katori T, Tocchetti CG, Ferlito M, Paolocci N, Fukuto JM. Comparison of the chemical biology of NO and HNO: An inorganic perspective. Prog Inorg Chem 2005, 54, 349-384.
12. Miranda KM. The chemistry of nitroxyl (HNO) and implications in biology. Coord Chem Rev 2005, 249, 433-455.
13. Samuni Y, Flores-Santana W, Krishna MC, Mitchell JB, Wink DA. The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation. Free Radic Biol Med 2009, 47, 419-423.
14. Lagercrantz C, Larsson T. Spin trapping of methyl radicals by the acyl nitroso compound Ph-C(= O)NO formed in the photochemical reaction between benzohydroxamic acid, dimethyl sulfoxide and hydrogen peroxide. An EPR study. Free Radic Res 1994, 20, 181-187.
15. Holder JW. Nitrobenzene carcinogenicity in animals and human hazard evaluation. Toxicol Ind Health 1999, 15, 445-457.
16. Hirota K, Itano HA, Vedvick TS. Oxidative degradation of haemoglobin by nitrosobenzene in the erythrocyte. Biochem J 1978, 174, 693-697.
17. Niufar NN, Haycock FL, Wesemann JL, MacStay JA, Heasley VL, Kovacic P. Reduction potentials of conjugated aliphatic ketones, oximes, and imines: correlation with structure and bioactivity. Rev Mex Chem Soc 2002, 46, 307-312.
18. Jacobs GP. Non-nitro radiation sensitizers. Int J Radiat Biol Relat Stud Phys Chem Med 1985, 49, 887-890.
19. Russell GA. In 'Radical Ions'. New York: Interscience 1968, 87-150.
20. Kovacic P, Cooksy AL. Electron transfer as a potential cause of diacetyl toxicity in popcorn lung disease. Rev Environ Contam Toxicol 2010, 204, 133-148.
21. Kovacic P, Somanathan R. Pulmonary toxicity and environmental contamination: radicals, electron transfer, and protection by antioxidants. Rev Environ Contam Toxicol 2009, 201, 41-69.
22. Kovacic P. Novel electrochemical approach to enhanced toxicity of 4-oxo-2-nonenal vs. 4-hydroxy-2-nonenal (role of imine): oxidative stress and therapeutic modalities. Med Hypotheses 2006, 67, 151-156.
23. Kovacic P. Unifying mechanism for bacterial cell signalers (4,5-dihydroxy- 2,3-pentanedione, lactones and oligopeptides): electron transfer and reactive oxygen species. Practical medical features. Med Hypotheses 2007, 69, 1105-1110.
24. Portanova P, Russo T, Pellerito O, Calvaruso G, Giuliano M, Vento R, Tesoriere G. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 2008, 33, 325-331.
25. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001, 98, 10833-10838.
26. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10, 3839-3852.
27. Tang DG, Li L, Zhu Z, Joshi B, Johnson CR, Marnett LJ, Honn KV, Crissman JD, Krajewski S, Reed JC, Timar J, Porter AT. BMD188, A novel hydroxamic acid compound, demonstrates potent antiprostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases. Pathol Oncol Res 1998, 4, 179-190.
28. Jacintho JD, Kovacic P. Neurotransmission and neurotoxicity by nitric oxide, catecholamines, and glutamate: unifying themes of reactive oxygen species and electron transfer. Curr Med Chem 2003, 10, 2693-2703.
29. Choe CU, Lewerenz J, Fischer G, Uliasz TF, Espey MG, Hummel FC, King SB, Schwedhelm E, Böger RH, Gerloff C, Hewett SJ, Magnus T, Donzelli S. Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neurochem 2009, 110, 1766-1773.
30. Wink DA, Feelisch M, Fukuto J, Chistodoulou D, Jourd'heuil D, Grisham MB, Vodovotz Y, Cook JA, Krishna M, DeGraff WG, Kim S, Gamson J, Mitchell JB. The cytotoxicity of nitroxyl: possible implication for the pathophysiological role of NO. Free Radic Biol Med 1999, 26, 1305-1313.
31. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004, 101, 18030-18035.
32. Cao Q, Yu C, Xue R, Hsueh W, Pan P, Chen Z, Wang S, McNutt M, Gu J. Autophagy induced by suberoylanilide hydroxamic acid in Hela S3 cells involves inhibition of protein kinase B and up-regulation of Beclin 1. Int J Biochem Cell Biol 2008, 40, 272-283.
33. Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A, Baird WM. Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells. Bioorg Med Chem Lett 2005, 15, 1283-1287.
34. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001, 115, 287-297.
35. Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Müller C, Beck JF. Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells. Cancer Lett 2006, 232, 148-160.
36. Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades N. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Invest Ophthalmol Vis Sci 2009, 50, 4072-4079.
37. Sangeetha SR, Singh N, Vender JR, Dhandapani KM. Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells. Endocrine 2009, 35, 389-396.
38. Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Mol Cancer Ther 2009, 8, 1596-1605.
39. Carlisi D, Lauricella M, D'Anneo A, Emanuele S, Angileri L, Di Fazio P, Santulli A, Vento R, Tesoriere G. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009, 45, 2425-2438.
40. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q. Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 2006, 281, 10508-10515.
41. Jiang X, Tsang YH, Yu Q. c-Myc overexpression sensitizes Bimmediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int J Biochem Cell Biol 2007, 39, 1016-1025.
42. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007, 67, 5318-5327.
43. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005, 16, 1125-1138.
44. Said TK, Moraes RC, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res 2001, 3, 122-133.
45. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005, 125, 1045-1052.
46. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin- A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003, 278, 12579-12589.
47. Forman HG, Cadenas E. Oxidative stress and signal transduction. In 'Oxidative Stress and Signal Transduction.' Chapman and Hall, New York, 1997.
48. Hancock GT. 'Cell Signaling.' Oxford University Press, New York, 2000.
49. Demple B. Oxidative stress and free radical signal transduction. In 'Handbook of Cell Signaling.' Academic Press, New York, 2004, 191-195.
50. Kovacic P, Pozos RS. Cell signaling (mechanism and reproductive toxicity): redox chains, radicals, electrons, relays, conduit, electrochemistry, and other medical implications. Birth Defects Res C Embryo Today 2006, 78, 333-344.
51. Kovacic P. Protein electron transfer (mechanism and reproductive toxicity): iminium, hydrogen bonding, homoconjugation, amino acid side chains (redox and charged), and cell signaling. Birth Defects Res C Embryo Today 2007, 81, 51-64.
52. Cerc G. Membrane electrostatics. Biochem Biophys Acta 1990, 1031, 311-382.
53. Kovacic P. Simplifying the complexity of cell signaling in medicine and the life sciences: Radicals and electrochemistry. Med Hypotheses 2010, 74, 769-771.
54. Kovacic P, Pozos RS. Bioelectronome. Integrated approach to receptor chemistry, radicals, electrochemistry, cell signaling, and physiological effects based on electron transfer. J Recept Signal Transduct Res 2007, 27, 261-294.
55. Kovacic P, Pozos RS, Draskovich CD. Unifying electrostatic mechanism for receptor-ligand activity. J Recept Signal Transduct Res 2007, 27, 411-431.
56. Kovacic P, Draskovich CD, Pozos RS. Unifying electrostatic mechanism for phosphates and sulfates in cell signaling. J Recept Signal Transduct Res 2007, 27, 433-443.
57. Kovacic P. Unifying electrostatic mechanism for metal cations in receptors and cell signaling. J Recept Signal Transduct Res 2008, 28, 153-161.
58. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004, 10, 2289-2298.
59. Muri EM, Nieto MJ, Sindelar RD, Williamson JS. Hydroxamic acids as pharmacological agents. Curr Med Chem 2002, 9, 1631-1653.
60. Koncic MZ, Rajic Z, Petric N, Zorc B. Antioxidant activity of NSAID hydroxamic acids. Acta Pharm 2009, 59, 235-242.
61. Kuzelová K, Pluskalová M, Brodská B, Otevrelová P, Elknerová K, Grebenová D, Hrkal Z. Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J Cell Biochem 2010, 109, 184-195.
62. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 2009, 107, 600-608.
63. Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, Wang Z, Osman I, Lee P. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009, 1, 62-71.
64. Wang L, Persons KS, Jamieson D, Flanagan JN, Hsu HH, Holick MF, Luo Z, Sakaki T, Urushino N, Faller DV, Chen TC. Prostate 25-hydroxyvitamin D-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor. Anticancer Res 2008, 28, 2009-2013.
65. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon- Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60, 5165-5170.
66. Dalgard CL, Van Quill KR, O'Brien JM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 2008, 14, 3113-3123.
67. Zhuang ZG, Fei F, Chen Y, Jin W. Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin 2008, 29, 1459-1466.
68. Zhou Q, Shaw PG, Davidson NE. Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat 2009, 117, 443-451.
69. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 2002, 99, 11700-11705.
70. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006, 15, 187-191.
71. Lee EM, Shin S, Cha HJ, Yoon Y, Bae S, Jung JH, Lee SM, Lee SJ, Park IC, Jin YW, An S. Suberoylanilide hydroxamic acid (SAHA) changes microRNA expression profiles in A549 human non-small cell lung cancer cells. Int J Mol Med 2009, 24, 45-50.
72. Hölsken A, Eyüpoglu IY, Lueders M, Tränkle C, Dieckmann D, Buslei R, Hahnen E, Blümcke I, Siebzehnrübl FA. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006, 112, 205-215.
73. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 2004, 9, 573-582.
74. Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 2006, 12, 5570-5577.
75. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res 2005, 11, 3958-3965.
76. Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006, 79, 259-270.
77. Jiang XX, Zhang QL, Chen XY, Wu WL, Shen ZX, Zhao WL. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009, 17, 1215-1219.
78. Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol 2007, 35, 1801-1811.
79. Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, Tsujii H, Matsubara H. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamicacid- containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29, 4433-4438.
80. Tavares TS, Nanus D, Yang XJ, Gudas LJ. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 2008, 7, 1607-1618.
81. Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007, 110, 313-322.
82. Fiskus W, Wang Y, Joshi R, Rao R, Yang Y, Chen J, Kolhe R, Balusu R, Eaton K, Lee P, Ustun C, Jillella A, Buser CA, Peiper S, Bhalla K. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res 2008, 14, 6106-6115.
83. Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007, 105, 297-309.
84. Beltran AS, Sun X, Lizardi PM, Blancafort P. Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 2008, 7, 1080-1090.
85. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8, 1589-1595.
86. Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, Choe TB, Park IC. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 2008, 73, 1005-1012.
87. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor- induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004, 128, 740-748.
88. Rundall BK, Denlinger CE, Jones DR. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in nonsmall cell lung cancer. Surgery 2005, 138, 360-367.
89. Kim JC, Shin ES, Kim CW, Roh SA, Cho DH, Na YS, Kim TW, Kim MB, Hyun YL, Ro S, Kim SY, Kim YS. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res 2009, 29, 3027-3034.
90. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrialmediated apoptosis in human melanoma cell lines. J Gene Med 2007, 9, 440-451.
91. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response f human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 2006, 5, 1967-1974.
92. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15, 2818-2828.
93. Yeh CC, Deng YT, Sha DY, Hsiao M, Kuo MY. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAILinduced apoptosis through increase DR5 expression. Mol Cancer Ther 2009, 8, 2718-2725.
94. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 2007, 6, 51-60.
95. Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007, 6, 2976-2984.
96. Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 2006, 6, 183.
97. Kovacic P. Fundamental, electron transfer mechanism by pyrylium-type ions for the anticancer drugs 5,6-dimethylxanthenone- 4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA). Curr Med Chem Anticancer Agents 2005, 5, 501-506.
98. Kovacic P. Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications. Med Hypotheses 2007, 69, 510-516.
99. Drahl C. Fixing function in cystic fibrosis. Chem Eng News 2009, 87, 35.
100. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, Thomas PJ, Matsumura Y, Skach WR, Gentzsch M, Riordan JR, Sorscher EJ, Okiyoneda T, Yates JR 3rd, Lukacs GL, Frizzell RA, Manning G, Gottesfeld JM, Balch WE. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010, 6, 25-33.
101. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009, 284, 6782-6789.
102. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009, 25, 207-212.
103. Plewe MB, Butler SL, Dress KR, Hu Q, Johnson TW, Kuehler JE, Kuki A, Lam H, Liu W, Nowlin D, Peng Q, Rahavendran SV, Tanis SP, Tran KT, Wang H, Yang A, Zhang J. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors. J Med Chem 2009, 52, 7211-7219.
104. Kovacic P, Somanathan R. Beneficial effects of antioxidants in relation to carcinogens, toxins and various illnesses. In 'Frontiers in Antioxidant Research.' Nova Science, New York, 2006, 1-38.
105. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 1, 166.
106. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor- Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9, 3578-3588.
107. Krug LM, Curley T, Schwartz L, Richardson S, Marks P, Chiao J, Kelly WK. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7, 257-261.
108. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23, 3923-3931.
109. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49, 502-507. (Pubitemid 351298334)
110. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/ or metastatic head and neck cancer. Invest New Drugs 2008, 26, 81-87.
111. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31-39. (Pubitemid 46053039)
112. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111, 1060-1066.
113. Rice CP, Park YB, Adam F, Abdul-Baki AA, Teasdale JR. Hydroxamic acid content and toxicity of rye at selected growth stages. J Chem Ecol 2005, 31, 1887-1905.